Trial · NCT02014519
Registered outcomes37
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 37
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Seropositive Subjects in Terms of Anti-pertussis Toxin (Anti-PT) Concentrations | At the time of enrollment of each subject (Day 0) | Seropositivity was defined as anti-PT IgG levels above the sensitivity limit of the assay (\> 0.3 Optical Density (OD) units) |
| Primary | Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels strongly indicative of current/recent infection was greater than or equal to (≥) 1.5 OD units |
| Primary | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels indicative of current/recent infection was greater than or equal to (≥) 1.0 OD units. |
| Primary | Number of Seronegative Subjects in Terms of Anti-PT Concentrations | At the time of enrollment of each subject (Day 0) | Seronegativity was defined as anti-PT IgG levels under the sensitivity limit of the assay (≤ 0.3 OD units) |
| Secondary | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Age) | At the time of enrollment of each subject (Day 0). | Seropositivity was defined as anti-PT IgG levels above the sensitivity limit of the assay (\> 0.3 OD units). |
| Secondary | Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Age) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels strongly indicative of current/recent infection was greater than or equal to (≥) 1.5 OD units |
| Secondary | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Age) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels indicative of current/recent infection was greater than or equal to (≥) 1.0 OD units. |
| Secondary | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Age) | At the time of enrollment of each subject (Day 0) | Seronegativity was defined as anti-PT IgG levels under the sensitivity limit of the assay (≤ 0.3 OD units) |
| Secondary | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Gender) | At the time of enrollment of each subject (Day 0) | Seropositivity was defined as anti-PT IgG levels above the sensitivity limit of the assay (\> 0.3 OD units) |
| Secondary | Number of Subjects With Anti-PT IgG Levels Strongly Indicative of Current/Recent Infection (by Gender) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels strongly indicative of current/recent infection was greater than or equal to (≥) 1.5 OD units |
| Secondary | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Gender) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels indicative of current/recent infection was greater than or equal to (≥) 1.0 OD units. |
| Secondary | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Gender) | At the time of enrollment of each subject (Day 0) | Seronegativity was defined as anti-PT IgG levels under the sensitivity limit of the assay (≤ 0.3 OD units) |
| Secondary | Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Gender) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels not indicative of current/recent infection was smaller than (\<) 1.0 OD units. |
| Secondary | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | Seropositivity was defined as anti-PT IgG levels above the sensitivity limit of the assay (\> 0.3 OD units). A long-lasting cough was defined as any cough that lasted for more than (≥) 3 weeks in the previous 12 months. |
| Secondary | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | Seronegativity was defined as anti-PT IgG levels under the sensitivity limit of the assay (≤ 0.3 OD units). A long-lasting cough was defined as any cough that lasted for more than (≥) 3 weeks in the previous 12 months. |
| Secondary | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels indicative of current/recent infection was greater than or equal to (≥) 1.0 OD units. A long-lasting cough was defined as any cough that lasted for more than (≥) 3 weeks in the previous 12 months. |
| Secondary | Number of Subjects With Anti-PT IgG Levels Not Indicative of Current/Recent Infection (by Recent History of Long-lasting Cough) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels not indicative of current/recent infection was smaller than (\<) 1.0 OD units. A long-lasting cough was defined as any cough that lasted for more than (≥) 3 weeks in the previous 12 months. |
| Secondary | Number of Seropositive Subjects in Terms of Anti-PT Concentrations (by Smoking Status) | At the time of enrollment of each subject (Day 0) | Seropositivity was defined as anti-PT IgG levels above the sensitivity limit of the assay (\> 0.3 OD units) |
| Secondary | Number of Seronegative Subjects in Terms of Anti-PT Concentrations (by Smoking Status) | At the time of enrollment of each subject (Day 0) | Seronegativity was defined as anti-PT IgG levels under the sensitivity limit of the assay (≤ 0.3 OD units) |
| Secondary | Number of Subjects With Anti-PT IgG Levels Indicative of Current/Recent Infection (by Smoking Status) | At the time of enrollment of each subject (Day 0) | The cut-off value for anti-PT IgG levels indicative of current/recent infection was greater than or equal to (≥) 1.0 OD units. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02014519/registered